File:Cardiovascular risk comparisons of non-steroidal anti-inflammatory agents in the TRICARE population (IA cardiovascularri109451953).pdf
Original file (1,275 × 1,650 pixels, file size: 620 KB, MIME type: application/pdf, 70 pages)
Captions
Summary[edit]
Cardiovascular risk comparisons of non-steroidal anti-inflammatory agents in the TRICARE population ( ) | ||
---|---|---|
Author |
Lefebvre, Kim L. |
|
Title |
Cardiovascular risk comparisons of non-steroidal anti-inflammatory agents in the TRICARE population |
|
Publisher |
Monterey, California. Naval Postgraduate School |
|
Description |
This report examines differences in risk of myocardial infarction and stroke (cardiovascular events) between the cyclooxygenase-2 (COX-2) inhibitors Rofecoxib, Celecoxib, and Valdecoxib, and the traditional nonsteroidal anti-inflammatory agents (NSAIDs) Naproxen and Ibuprofen, as well as Meloxicam, a preferential COX-2 inhibitor. The population studied was the DoD TRICARE beneficiary population greater than age 40 during the study period. In September of 2004, Rofecoxib was removed from the market due to an increased risk of cardiovascular events. In February of 2005, the Food and Drug Administration (FDA) examined the entire class of COX-2 inhibitors and recommended that Valdecoxib also be withdrawn from the market. According to Department of Defense TRICARE prescription records, COX-2 inhibitor prescription numbers were increasing rapidly and more than $7 million was spent on these agents alone in July of 2004. Logistic regression was used to analyze TRICARE prescription and diagnosis data from calendar years 2002, 2003, and 2004 for cardiovascular event risk comparisons among various NSAIDs. Rofecoxib was found to have a significantly increased risk of cardiovascular events when compared with all other medications in the study, including Valdecoxib. Odds ratios for comparison with Valdecoxib, Celecoxib, Meloxicam, Ibuprofen, and Naproxen were 1.09, 1.14, 1.15, 1.28, and 1.23. Valdecoxib showed a significant increase compared to Ibuprofen, Naproxen, and Celecoxib (odds ratios 1.21, 1.16, and 1.06). Ibuprofen showed a significantly decreased risk relative to all medications except Naproxen. When considering only cardiovascular risk, this study suggests prescribers should consider Ibuprofen or Naproxen as the primary agent of choice, with Meloxicam, and Celecoxib as reasonable second choices. Ultimately, the decision must also weigh the patient's risk of gastrointestinal side effects and cost of therapy. Subjects: Steroids; Myocardial infarction; Medicine; Research; Cardiovascular system; Ibuprofen |
|
Language | English | |
Publication date | September 2005 | |
Current location |
IA Collections: navalpostgraduateschoollibrary; fedlink |
|
Accession number |
cardiovascularri109451953 |
|
Source | ||
Permission (Reusing this file) |
Approved for public release, distribution unlimited |
Licensing[edit]
Public domainPublic domainfalsefalse |
This work is in the public domain in the United States because it is a work prepared by an officer or employee of the United States Government as part of that person’s official duties under the terms of Title 17, Chapter 1, Section 105 of the US Code.
Note: This only applies to original works of the Federal Government and not to the work of any individual U.S. state, territory, commonwealth, county, municipality, or any other subdivision. This template also does not apply to postage stamp designs published by the United States Postal Service since 1978. (See § 313.6(C)(1) of Compendium of U.S. Copyright Office Practices). It also does not apply to certain US coins; see The US Mint Terms of Use.
|
||
This file has been identified as being free of known restrictions under copyright law, including all related and neighboring rights. |
https://creativecommons.org/publicdomain/mark/1.0/PDMCreative Commons Public Domain Mark 1.0falsefalse
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 10:55, 15 July 2020 | 1,275 × 1,650, 70 pages (620 KB) | Fæ (talk | contribs) | FEDLINK - United States Federal Collection cardiovascularri109451953 (User talk:Fæ/IA books#Fork8) (batch 1993-2020 #10887) |
You cannot overwrite this file.
File usage on Commons
The following page uses this file:
Metadata
This file contains additional information such as Exif metadata which may have been added by the digital camera, scanner, or software program used to create or digitize it. If the file has been modified from its original state, some details such as the timestamp may not fully reflect those of the original file. The timestamp is only as accurate as the clock in the camera, and it may be completely wrong.
Short title | Cardiovascular risk comparisons of non-steroidal anti-inflammatory agents in the TRICARE population |
---|---|
Author | Lefebvre, Kim L. |
Software used | Lefebvre, Kim L. |
Conversion program | Acrobat Distiller 6.0.1 (Windows) |
Encrypted | no |
Page size | 612 x 792 pts (letter) |
Version of PDF format | 1.4 |